Upload
soravoot-rujivipat
View
212
Download
0
Embed Size (px)
Citation preview
8/14/2019 Abstract SD
1/2
Graduate seminar 1/2013
November 15, 2013
Title The application of polymer in stabilization of drug solubility in solid
dispersions
Speaker Miss Woralak Leelasornchai
Master of Sciences in Pharmaceutical chemistry and natural products /2ndyear
Advisor Asst. Prof. Dr. Soravoot Rujivipat
Co-advisor Asst. Prof. Dr. Waree Tiyaboonchai
Asst. Prof. Dr. A-nan Ounarun
Dr. Nutsawadee Apichartwattana
ABSTRACT
Low aqueous solubility is a common characteristic in todaysbiopharmaceuticswhichis a critical determinant of oral bioavailability [1]. There are many techniques which are used
to enhance the aqueous solubility like physical, chemical and others techniques. Solid
dispersion technology has been used for improving the dissolution rate and bioavailability of
poorly water soluble drugs [24]. Solid dispersions are typically prepared by incorporation of
the poorly soluble drug into a water-soluble carrier via melt-extrusion or coprecipitation
technique [5, 6], resulting in Such processes result in amorphous drug dispersions [7].
Although the amorphous drug dissolves faster compared to its crystalline alternatives, it is not
physically stable and may undergo unpredictable crystallization during the shelf-life [810].
The stabilization of amorphous drug solubility by the incorporation of polymer as
inhibitory effect has been introduced. The roles of polymer in stabilization mechanism could
be: to increasing glass transition temperature of miscible mixture (anti-platicization by the
polymer); specific drug-polymer interaction (e.g., hydrogen bonding, ion-dipole) [1113] and
an increase in the activation energy for nucleation or alteration of chemical potential of a
drug [14-15]. These results in a decrease in local molecular mobility at regular storage
temperatures, then the recrystallization would be decreased.
Keywords;solid dispersion, stabilization mechanism, anti-plasticization, drug-polymer
interaction, recrystallization
8/14/2019 Abstract SD
2/2
Graduate seminar 1/2013
November 15, 2013
References
1. Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in
vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J
Control Release. 2008 ; 129(1):1-10.
2. Sekiguchi K, Obi N. Studies on absorption of eutectic mixture. I. A comparison of the behavior of
eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull. 1961;
9:86672.
3. Dannenfelser RM, He H, Joshi Y, Bateman S, Serajuddin AT. Development of clinical dosage
forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid
dispersion carrier system. J Pharm Sci. 2004; 93(5):1165-75.
4. Craig DQ. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J
Pharm. 2002; 231(2):131-44.
5. Verreck G, Vandecruys R, De Conde V, Baert L, Peeters J, Brewster ME. The use of three different
solid dispersion formulations--melt extrusion, film-coated beads, and a glass thermoplastic system--to
improve the bioavailability of a novel microsomal triglyceride transfer protein inhibitor. J Pharm Sci.
2004; 93(5):1217-28.
6. Sethia S, Squillante E. Physicochemical characterization of solid dispersions of carbamazepine
formulated by supercritical carbon dioxide and conventional solvent evaporation method. J Pharm
Sci. 2002; 91(9):1948-57.
7. Forster A, Hempenstall J, Rades T. Characterization of glass solutions of poorly water-soluble
drugs produced by melt extrusion with hydrophilic amorphous polymers. J Pharm Pharmacol. 2001
Mar; 53(3):303-15
8. Kimura K, Hirayama F, Arima H, Uekama K. Effects of aging on crystallization, dissolution and
absorption characteristics of amorphous tolbutamide-2-hydroxypropyl-beta-cyclodextrin complex.
Chem Pharm Bull (Tokyo). 2000; 48(5):646-50.
9. Chiou WL. Pharmaceutical applications of solid dispersion systems: X-ray diffraction and aqueous
solubility studies on griseofulvin-polyethylene glycol 6000 systems. J Pharm Sci. 1977; 66(7):989-91.
10. Suzuki H, Sunada H. Some Factors Influencing the Dissolution of Solid Dispersions with
Nicotinamide and Hydroxypropylmethylcellulose as Combined Carriers. Chemical & Pharmaceutical
Bulletin. 1998; 46(6):1015-20.
11. Khougaz K, Clas SD. Crystallization inhibition in solid dispersions of MK-0591 and
poly(vinylpyrrolidone) polymers. J Pharm Sci. 2000; 89(10):1325-34.
12. Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and
indomethacin in amorphous molecular dispersions. Pharm Res. 1997; 14(12):1691-8.
13. Matsumoto T, Zografi G. Physical properties of solid molecular dispersions of indomethacin with
poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin
crystallization. Pharm Res. 1999; 16(11):1722-8.
14. Marsac PJ, Konno H, Taylor LS. A comparison of the physical stability of amorphous felodipine
and nifedipine systems. Pharm Res. 2006; 23(10):2306-16.
15. Marsac PJ, Shamblin SL, Taylor LS. Theoretical and practical approaches for prediction of drug-
polymer miscibility and solubility. Pharm Res. 2006; 23(10):2417-26.